Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes

This article was originally published in The Tan Sheet

Executive Summary

Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry

You may also be interested in...



Pepto-Bismol Cherry Flavor Marks First Line Extension In A Decade

The debut of cherry-flavored Pepto-Bismol represents the first time the taste of the well-known stomach remedy has been changed in the product's hundred-year history, Procter & Gamble says

Pepto-Bismol Cherry Flavor Marks First Line Extension In A Decade

The debut of cherry-flavored Pepto-Bismol represents the first time the taste of the well-known stomach remedy has been changed in the product's hundred-year history, Procter & Gamble says

Pepto-Bismol Cherry Flavor Marks First Line Extension In A Decade

The debut of cherry-flavored Pepto-Bismol represents the first time the taste of the well-known stomach remedy has been changed in the product's hundred-year history, Procter & Gamble says

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel